Prof Matthew Smith & Asso Prof Aaron Hansen on ARASENS trial

The ARASENS trial has redefined treatment for metastatic hormone-sensitive prostate cancer (mHSPC), showcasing the benefits of triplet therapy with androgen deprivation therapy (ADT), docetaxel, and darolutamide. The trial demonstrated significant improvement in overall survival, reducing the risk of death by 32.5%, with a manageable safety profile and maintained quality of life. Darolutamide's design minimizes blood-brain barrier penetration, reducing cognitive side effects and drug interactions, making it suitable for older, comorbid patients. This robust study, involving over 1,000 patients globally, supports triplet therapy as a new standard of care, particularly for chemotherapy-eligible patients, broadening treatment options and maximizing survival outcomes.